Steward Partners Investment Advisory LLC boosted its stake in Pfizer Inc. (NYSE:PFE) by 12.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 226,657 shares of the biopharmaceutical company’s stock after purchasing an additional 25,979 shares during the period. Steward Partners Investment Advisory LLC’s holdings in Pfizer were worth $8,209,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently modified their holdings of PFE. Beach Investment Management LLC. acquired a new position in shares of Pfizer during the second quarter valued at $5,214,000. DE Burlo Group Inc. increased its holdings in shares of Pfizer by 65.4% during the second quarter. DE Burlo Group Inc. now owns 6,957 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 2,750 shares during the period. Ballentine Partners LLC increased its holdings in shares of Pfizer by 82.7% during the second quarter. Ballentine Partners LLC now owns 63,731 shares of the biopharmaceutical company’s stock valued at $2,108,000 after purchasing an additional 28,850 shares during the period. Aspiriant LLC increased its holdings in shares of Pfizer by 2.1% during the second quarter. Aspiriant LLC now owns 38,427 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 776 shares during the period. Finally, Bridgewater Wealth & Financial Management LLC increased its holdings in shares of Pfizer by 10.6% during the second quarter. Bridgewater Wealth & Financial Management LLC now owns 37,363 shares of the biopharmaceutical company’s stock valued at $1,255,000 after purchasing an additional 3,577 shares during the period. 71.16% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Pfizer stock opened at $36.27 on Thursday. The stock has a market capitalization of $216,267.59, a PE ratio of 10.33, a P/E/G ratio of 2.05 and a beta of 0.91. Pfizer Inc. has a fifty-two week low of $31.67 and a fifty-two week high of $39.43. The company has a current ratio of 1.35, a quick ratio of 1.10 and a debt-to-equity ratio of 0.47.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.06. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. During the same period in the previous year, the company earned $0.47 earnings per share. Pfizer’s revenue was up .6% compared to the same quarter last year. analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer declared that its board has authorized a share buyback plan on Monday, December 18th that authorizes the company to repurchase $10.00 billion in shares. This repurchase authorization authorizes the biopharmaceutical company to buy shares of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

In related news, insider Douglas M. Lankler sold 50,000 shares of the stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $36.89, for a total value of $1,844,500.00. Following the completion of the transaction, the insider now owns 133,057 shares in the company, valued at approximately $4,908,472.73. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mikael Dolsten sold 69,699 shares of the stock in a transaction on Friday, March 9th. The shares were sold at an average price of $36.59, for a total value of $2,550,286.41. Following the completion of the transaction, the insider now owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock valued at $9,064,785 in the last quarter. 0.06% of the stock is currently owned by corporate insiders.

PFE has been the topic of a number of research analyst reports. UBS set a $40.00 price target on Pfizer and gave the company a “buy” rating in a report on Wednesday, December 6th. Sanford C. Bernstein set a $43.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Wednesday, January 17th. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price target on the stock in a report on Thursday, November 23rd. Finally, Morgan Stanley set a $41.00 price target on Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $39.40.

COPYRIGHT VIOLATION NOTICE: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/steward-partners-investment-advisory-llc-has-8-21-million-holdings-in-pfizer-inc-pfe/1956025.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.